The term leishmaniasis describes closely related diseases caused by approximately 30 distinct species, subspecies, and strains of leishmania parasites.
Fake versions of a drug to treat leishmaniasis have been discovered in Iran and Pakistan, the counterfeits falsely claim to contain the medicine meglumine antimoniate.
Leishmaniasis cases more than doubled in the last ten years, according to Sara Karlsson Söbirk, an infectious physician who in her thesis work at Lund University surveyed the disease’s presence in Sweden for just over 20 years.
After previously ravishing hundreds of people in Mohmand, Pakistan, a leishmaniasis outbreak has been reported in South Waziristan with hundreds of patients registered at the district headquarters hospital (DHQ) while others have sought treatment at the Bannu District Headquarters Hospital.
Most of the leishmaniasis cases were registered along North African country's Mediterranean coast west of the capital, Tripoli.
Uruguay health officials reported the first human leishmaniasis case in a minor from Salta.
Data indicate that the prewar trend of increasing incidence of cutaneous leishmaniasis accelerated during the beginning of armed conflict but declined after implementation of the comprehensive control program by the MENTOR Initiative.
Researchers at the University of York have identified genes in a parasite that could help clinicians predict drug treatment outcomes for patients with visceral leishmaniasis in Brazil.
Investigators developed a new strategy to identify the molecules that could be capable of eliminating the parasite.
ISC1 is an emerging Leishmania donovani population in the Nepalese highlands with a genome and metabolome which are distinct from strains from the most recent visceral leishmaniasis outbreak in the Indian sub-continent.